You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

Guidelines and links

British Thoracic Society / Scottish Intercollegiate Guidelines Network, UK (BTS / SIGN) (2014)

  • Children and adults with mild and moderate exacerbations of Asthma should be treated by bronchodilators given from a pMDI + Spacer/Holding Chamber with doses titrated according to clinical response
  • Use Spacer/Holding Chamber with facemask for children aged 0 to 5 years
  • Use pMDI + Spacer/Holding Chamber in children 5-12 years of age receiving corticosteroids

National Institute for Clinical Excellence, UK (NICE) (2015)

  • Spacer/Holding Chamber recommended with a facemask where necessary for both corticosteroids and bronchodilators (Children under 5)
  • A press and breathe pMDI used with an appropriate Spacer/Holding Chamber is first choice for corticosteroids (Children aged 5-15 years)

Global Initiative on Asthma (GINA) (2014)

  • pMDI + dedicated Spacer/Holding Chamber with facemask is the recommended inhaler choice for children 4 years of age and younger
  • pMDI + dedicated Spacer/Holding Chamber with mouthpiece is the recommended inhaler choice for children between 4 and 5 years of age

Adverse events should be reported. Reporting forms and information can be found at
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

AeroChamber Plus is manufactured by Trudell Medical International. Distributed in the UK by GlaxoSmithKline.